These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12223126)

  • 1. Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.
    Reimer T; Koczan D; Müller H; Friese K; Thiesen HJ; Gerber B
    Breast Cancer Res; 2002; 4(5):R9. PubMed ID: 12223126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
    Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen.
    Mor G; Kohen F; Garcia-Velasco J; Nilsen J; Brown W; Song J; Naftolin F
    J Steroid Biochem Mol Biol; 2000; 73(5):185-94. PubMed ID: 11070347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors.
    Herrnring C; Reimer T; Jeschke U; Makovitzky J; Krüger K; Gerber B; Kabelitz D; Friese K
    Histochem Cell Biol; 2000 Mar; 113(3):189-94. PubMed ID: 10817673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
    Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
    Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
    Botti C; Buglioni S; Benevolo M; Giannarelli D; Papaldo P; Cognetti F; Vici P; Di Filippo F; Del Nonno F; Venanzi FM; Natali PG; Mottolese M
    Clin Cancer Res; 2004 Feb; 10(4):1360-5. PubMed ID: 14977837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF-II mRNA expression in breast cancer: predictive value and relationship to other prognostic factors.
    Fiore E; Campani D; Muller I; Belardi V; Giustarini E; Rossi G; Pinchera A; Giani C
    Int J Biol Markers; 2010; 25(3):150-6. PubMed ID: 20677165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FasL:Fas ratio--a prognostic factor in breast carcinomas.
    Reimer T; Herrnring C; Koczan D; Richter D; Gerber B; Kabelitz D; Friese K; Thiesen HJ
    Cancer Res; 2000 Feb; 60(4):822-8. PubMed ID: 10706087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
    Wang Y; Gong X; Zhang Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma.
    Bièche I; Onody P; Lerebours F; Tozlu S; Hacene K; Andrieu C; Vidaud M; Tubiana-Hulin M; Spyratos F; Lidereau R
    Cancer Lett; 2001 Dec; 174(2):173-8. PubMed ID: 11689293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diplotype Fas -1377A/-670G as a genetic marker to predict a lower risk of breast cancer in Chinese women.
    Xu Y; Deng Q; He B; Pan Y; Li R; Gao T; Sun H; Song G; Wang S; Cho WC
    Tumour Biol; 2014 Sep; 35(9):9147-61. PubMed ID: 24916571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
    Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
    J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; von Boguslawski K; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Wist E; Valvere V; Takayama S; Reed JC; Saksela E
    Clin Cancer Res; 2002 Mar; 8(3):811-6. PubMed ID: 11895913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.